^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Neocarzinostatin (zinostatin)

i
Other names: NSC 157365, NSC 69856, YM 881, YM-16881, Styrene maleic acid neocarzinostatin, NCS
Associations
Trials
Company:
Astellas
Drug class:
DNA synthesis inhibitor
Related drugs:
Associations
Trials
6ms
SMYD3 Modulates AMPK-mTOR Signaling Balance in Cancer Cell Response to DNA Damage. (PubMed, Cells)
Moreover, we found that SMYD3 can methylate AMPK at the evolutionarily conserved residues Lys411 and Lys424. Overall, our data revealed that SMYD3 can act as a bridge between the AMPK and mTOR pathways upon neocarzinostatin-induced DNA damage in gastrointestinal and breast cancer cells.
Journal
|
TSC2 (TSC complex subunit 2) • SMYD3 (SET And MYND Domain Containing 3)
|
Neocarzinostatin (zinostatin)
1year
Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis. (PubMed, Cancer Cell Int)
TMZ-induced cell death in the presence of calpain-2 expression appears to favor DNA repair and promote cell survival. We conclude from our experiments that calpain-2 expression represents a proteomic mode that is associated with higher resistance via "priming" GBM cells to TMZ chemotherapy. Thus, calpain-2 could serve as a prognostic factor for GBM outcome.
Journal • Tumor cell
|
TP53 (Tumor protein P53) • CASP3 (Caspase 3)
|
temozolomide • Neocarzinostatin (zinostatin)
2years
Preferential translation of p53 target genes. (PubMed, RNA Biol)
In order to separate these passive effects from active regulation of translation efficiency in response to p53 activation, we conducted a comprehensive analysis of translational regulation by comparative analysis of mRNA levels and ribosome densities upon DNA damage induced by neocarzinostatin in wild-type and TP53 HCT116 colorectal carcinoma cells. Thereby, we identified a specific group of mRNAs that are preferentially translated in response to p53 activation, many of which correspond to p53 target genes including MDM2, SESN1 and CDKN1A. By subsequent polysome profile analysis of SESN1 and CDKN1A mRNA, we could demonstrate that p53-dependent translational activation relies on a combination of inducing the expression of translationally advantageous isoforms and trans-acting mechanisms that further enhance the translation of these mRNAs.
Journal
|
TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
Neocarzinostatin (zinostatin)
over2years
Chemotherapy of HER2- and MDM2-Enriched Breast Cancer Subtypes Induces Homologous Recombination DNA Repair and Chemoresistance. (PubMed, Cancers (Basel))
Inhibition of MDM2 expression in the SKBR3 cell line (HER2 subtype) diminished the survival of cancer cells treated with doxorubicin, etoposide, and camptothecin. Moreover, we demonstrated that inhibition of MDM2 expression diminished DNA repair by homologous recombination (HR) and sensitized SKBR3 cells to a PARP inhibitor, olaparib. In H1299 (TP53) cells treated with neocarzinostatin (NCS), overexpression of MDM2 WT or E3-dead MDM2 C478S variant stimulated the NCS-dependent phosphorylation of ATM, NBN, and BRCA1, proteins involved in HR DNA repair...Using a proliferation assay, we showed that overexpression of MDM2 WT, but not MDM2 K454A, led to acquisition of resistance to NCS. The presented results indicate that, following chemotherapy, MDM2 WT was released from MDM2-NBN complex and efficiently degraded, hence allowing extensive HR DNA repair leading to the acquisition of chemoresistance by cancer cells.
Journal • BRCA Biomarker • PARP Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • MDM2 (E3 ubiquitin protein ligase) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin))
|
HER-2 overexpression • HER-2 negative • MDM2 overexpression
|
Lynparza (olaparib) • doxorubicin hydrochloride • etoposide IV • Neocarzinostatin (zinostatin)